Ebola hemorrhagic fever has emerged as an endemic threat in West Africa. With National Institutes of Health (NIH) support and under the leadership of Tulane University virologist Dr. Robert F. Garry, Autoimmune Technologies has been participating with several members of the Viral Hemorraghic Fever Consortium, or VHFC, to develop new diagnostic tests for Ebola fever.

The Consortium's trademarked ReEBOV rapid diagnostic test could have a significant impact on health care in West Africa and also fill a critical gap in bioterrorism defense. In February 2015, VHFC member and test kit manufacturer Corgenix Medical Corporation received FDA authorization and WHO listing for emergency use of this test. The Corgenix news release describing the ReEBOV test and the agencies' approval of it can be found on the Corgenix Web site here: Corgenix Release 26Feb2015. Working with the VHFC, Autoimmune Technologies developed a critical reagent for the ReEBOV test and now supplies Corgenix with this component of the test.

On behalf of the VHFC, in 2014 Dr. Garry and Tulane issued an appeal for help in dealing with and attempting to stop the devastation caused by the Ebola virus in Africa. Click here for more information about this appeal.

A news feature entitled Infectious Disease: Ebola's Lost Ward appears in Volume 513 of the journal Nature, published on September 24, 2014. This article offers an comprehensive view of some of the work being done by the members of the VHFC.